Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | SVP, Clinical Dev, Drug Safety | March 08, 2021 | March 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date March 08, 2021 · Filed March 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,346 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Tax withholding · Disposed 5,221 · Balance 147,346 F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2021 Filed Mar 10, 2021 22:38 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 5,221 | $33.37 | $174,224.77 |
DisclosureSEC source: 0001209191-21-019555 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,346 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 39,900 | $0.00 Strike: $53.01 | $0.00 |
DisclosureSEC source: 0001209191-21-015010 · doc4.xml · derivative · entry 2 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900 Underlying: Common Stock · 39,900 shares Expires 2031-02-24 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on March 1, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:25 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 20,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015010 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,567 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2022, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:33 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,728 | $41.99 | $114,548.72 |
DisclosureSEC source: 0001209191-20-062619 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,767 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,082 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-20-059427 · doc4.xml · derivative · entry 2 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,082 shares Expires 2024-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 21:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 7,082 | $14.58 | $103,220.15 |
DisclosureSEC source: 0001209191-20-059427 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 23:32 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,728 | $42.16 | $115,012.48 |
DisclosureSEC source: 0001209191-20-050049 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,413 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 23:45 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,728 | $33.61 | $91,688.08 |
DisclosureSEC source: 0001209191-20-035694 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,141 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 678 shares acquired on May 15, 2020 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:03 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $26.41 | $0.00 |
DisclosureSEC source: 0001209191-20-020121 · doc4.xml · derivative · entry 3 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2030-03-17 F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests March 1, 2021, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:03 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020121 · doc4.xml · nonDerivative · entry 2 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,191 F2 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2021, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| March 06, 2020 Filed Mar 19, 2020 00:03 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 6,525 | $39.71 | $259,107.75 |
DisclosureSEC source: 0001209191-20-020121 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,691 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| December 06, 2019 Filed Dec 10, 2019 01:13 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,442 | $47.39 | $115,726.38 |
DisclosureSEC source: 0001209191-19-059778 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,216 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| September 06, 2019 Filed Sep 11, 2019 00:31 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 5,541 | $41.68 | $230,948.88 |
DisclosureSEC source: 0001209191-19-049100 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,658 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| June 28, 2019 Filed Jul 3, 2019 00:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,873 | $45.00 | $129,285.00 |
DisclosureSEC source: 0001209191-19-040581 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,199 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 22:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $14.58 | $0.00 |
DisclosureSEC source: 0001209191-19-038295 · doc4.xml · derivative · entry 2 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,082 Underlying: Common Stock · 16,000 shares Expires 2024-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 22:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 16,000 | $14.58 | $233,200.00 |
DisclosureSEC source: 0001209191-19-038295 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:36 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,058 | $38.31 | $78,841.98 |
DisclosureSEC source: 0001209191-19-035678 · doc4.xml · nonDerivative · entry 1 Kouchakji Elias · CIK 0001775259 · SVP, Clinical Dev, Drug Safety 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,072 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. F2 · balance_after: Includes 618 shares acquired on May 15, 2019 through the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.